Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute traumatic spinal cord injury
Latest Information Update: 07 Sep 2023
At a glance
- Drugs FAB 117-HC (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; First in man
- Acronyms SPINE
- Sponsors Ferrer
- 08 Sep 2021 Planned End Date changed from 1 Mar 2022 to 1 Jul 2023.
- 08 Sep 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Jul 2022.
- 03 Oct 2019 Planned number of patients changed from 46 to 48.